1. In Vivo
  2. >>Market Access

FTC’s Salvos Against Biopharma To Reverberate Through 2024

 
• By Brenda Sandburg

The Federal Trade Commission broke new ground last year in its opposition to M&A transactions and challenge of Orange Book patent listings. The biopharma community is waiting to see if deals will face similar hurdles in 2024 and whether there will be legal battles if manufacturers of drug-device combination products decline to delist their patents. Researchers advocate that the FTC extend its inquiry to device patents on GLP-1 receptor agonists, including Wegovy and Ozempic.  

FTC building
Federal Trade Commission took aggressive actions against the biopharma industry last year • Source: Shutterstock

The US Federal Trade Commission took on the biopharmaceutical industry last year with a series of unusual enforcement actions challenging proposed mergers and industry patent listings. Stakeholders are watching to see if the agency will maintain its aggressive stance against the industry and what the fallout will be as some companies have refused to concede to its demands.

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on In Vivo for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Market Access

Biotech Leaders Ponder Trump’s Tariff Ramifications

 
• By Joseph Haas, Mary Jo Laffler, and Jessica Merrill

Several biotech execs said they don’t expect much impact from the Trump administration’s threatened tariffs but are reviewing business practices to prepare.

Reforming The Rx Rulers: A New Script For PBMs

 
• By Andrew Cox

As PBMs shift to value-based contracts, federal and state efforts seek to reduce drug costs, increase transparency and tackle anticompetitive practices.

Regenxbio’s Triple Threat: Partnered Programs, DMD Progress And In-House Manufacturing

 
• By David Wild

Regenxbio is riding a wave these days, with all three of its clinical-stage programs set to reach critical milestones this year and recent positive news on its DMD gene therapy, just as Sarepta suffered a setback with a death related to its DMD treatment. In Vivo spoke with CEO Curran Simpson about the company’s plans and strategic decisions.

Therapeutic Or Cosmetic? Patent Strategies For Dual-Use Innovations

 
• By Mairi Rudkin

In the pharma and cosmetic sectors, innovation often arises from new uses for known compounds. While the compounds may not be patentable, their new applications can be. European law allows patents on substances used in medical methods, but not on the methods themselves.

More from In Vivo

Deals Shaping The Industry, March 2025

 
• By In Vivo Team

An interactive look at pharma, medtech and diagnostics deals made during March 2025. Data courtesy of Biomedtracker.

From Brain Waves to Better Outcomes: Inside Alto Neuroscience’s Biomarker Strategy

 
• By David Wild

Alto Neuroscience’s CEO, Amit Etkin, believes the company’s biomarker-based approach to psychiatric treatment is the way forward.

Merck’s Digital Biomarker Strategy For Commercial Gains In Neurology

 
• By Jo Shorthouse

The integration of digital health tools into clinical research and patient care is gaining momentum, and Merck KGaA, Darmstadt, Germany is not letting the grass grow under its feet. With an approach to digital biomarkers, the company is seeking to redefine how neurological diseases are monitored and managed.